scholarly journals Serum O-Glycosylated Hepatitis B Surface Antigen Levels in Patients with Chronic Hepatitis B During Nucleos(t)ide Analog Therapy

2021 ◽  
Author(s):  
Ayato Murata ◽  
Kiyohiko Angata ◽  
Maki Sogabe ◽  
Shunsuke Sato ◽  
Takafumi Ichida ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hbv Dna ◽  
Viral Kinetics ◽  
Baseline Serum ◽  
Dna And Rna ◽  
Genotype C

Abstract Serum hepatitis B surface antigen (HBsAg) is a component of hepatitis B virus (HBV) virions and non-infectious subviral particles (SVPs). O-glycosylation of the PreS2 domain of middle HBsAg protein is a distinct characteristic of genotype C HBV virions versus SVPs. We measured serum O-glycosylated HBsAg levels in 47 treatment-naïve patients with genotype C chronic hepatitis B (CHB) at baseline and after 48 weeks of nucleos(t)ide analog (NA) therapy by immunoassay using a monoclonal antibody against the O-glycosylated PreS2 domain of middle HBsAg, and analyzed their correlations with conventional HBV marker levels. At baseline, serum O-glycosylated HBsAg levels were significantly correlated with HBV DNA, HBsAg, and hepatitis B-core related antigen (HBcrAg) levels. HBV DNA and O-glycosylated HBsAg levels were decreased after 48 weeks of NA therapy. The correlation between O-glycosylated HBsAg and HBsAg or HBcrAg levels was lost in patients who achieved undetectable HBV DNA. HBV DNA and RNA were detected in the O-glycosylated HBsAg-binding serum fraction, and the proportion of HBV RNA increased during NA therapy. In conclusion, serum O-glycosylated HBsAg levels change during NA therapy and may reflect combined serum HBV DNA and RNA virion levels, and an O-glycosylated HBsAg-based immunoassay may allow monitoring viral kinetics during NA therapy.

Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B

2010 ◽  
Vol 15 (8) ◽  
pp. 1133-1139 ◽  
Author(s):  
Tung-Hung Su ◽  
Ching-Sheng Hsu ◽  
Chi-Ling Chen ◽  
Chen-Hua Liu ◽  
Yi-Wen Huang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hbv Dna ◽  
Serum Hepatitis ◽  
Antigen Concentration

scholarly journals Reduction of Hepatitis B Surface Antigen More Pronounced In Pegylated Interferon Alpha Therapy Combined With Nucleotide Analogues Than Nucleoside Analogues In Chronic Hepatitis B Patients

2021 ◽  
Author(s):  
Yiran Xie ◽  
Haoxiang Zhu ◽  
Yifei Guo ◽  
Zhenxuan Ma ◽  
Xun Qi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hbeag Seroconversion ◽  
Pegylated Interferon ◽  
Hbv Dna ◽  
Nucleoside Analogues ◽  
Nucleotide Analogues

Abstract Background: Nucleotide analogues (NTs) monotherapy may have a greater effect on reducing hepatitis B surface antigen (HBsAg) than nucleoside analogues (NSs) due to their immunomodulatory function. However, this superiority remains unknown when combined with pegylated interferon α (PegIFNα). The study aimed to explore whether NTs have greater antiviral effects than NSs in combination therapy with PegIFNα. Methods: Chronic hepatitis B (CHB) patients treated with PegIFNα plus nucleos(t)ide analogues (NAs) were retrospectively recruited. Efficacy and the predictors of hepatitis B surface antigen (HBsAg) reduction > 1 log10 IU/mL at 48 weeks were analyzed. Results: A total of 95 patients were investigated, including in PegIFNα plus NSs group and in PegIFNα plus NTs group. Propensity score matching (PSM) was performed. The PegIFNα + NTs group had a greater reduction of HBsAg (−3.48 vs −2.33 log10 IU/mL, P = 0.038) and a higher proportion of patients with HBsAg reduction > 1 log10 IU/mL (100.0% vs 72.2%, P =0.003) even after PSM. However, HBsAg and hepatitis B e-antigen (HBeAg) loss rates, HBeAg seroconversion rates, degree of HBeAg and hepatitis B virus (HBV) DNA decline, HBV DNA undetectable rates, and alanine aminotransferase (ALT) normalization rates showed no significant differences. Higher platelet counts (OR = 1.043, 95%CI = 1.002–1.085) and PegIFNα plus NTs (OR = 77.861, 95%CI = 3.923–1545.273) were independent predictors for HBsAg reduction > 1 log10 IU/mL at 48 weeks. Conclusion: This study suggests that PegIFNα plus NTs led to more HBsAg reduction.

A STUDY OF HEPATITIS B VIRUS GENOTYPES IN CHRONIC HEPATITIS B PATIENTS

2011 ◽  
pp. 25-29
Author(s):  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Clinical Laboratory ◽  
Laboratory Data ◽  
Hbv Dna ◽  
Hbv Genotypes ◽  
B Virus ◽  
Virus Genotypes ◽  
Genotype C

Aims: To measure the prevalence of HBV genotypes in chronic hepatitis B patients and their relation to HBeAg and HBV DNA level. Methods: 81 patients were enrolled in this study from January 2009 to December 2010. Clinical, laboratory data were collected during the patient’s hospitalization. Sera were quantitatively tested for HBeAg and HBV DNA. HBV genotyping was made by real-time PCR. Results: Among the 81 patients, 60.5% had genotype B, 26.7% had genotype C and 8.6% had mixed genotype B-C. Prevalence of symptoms (fatigue, anorexia, insomnia...) was higher in genotype C than in genotype B. Genotype C patients had positivity higher HBeAg than genotype B patients (56% vs. 38,8%, p <0.05). The rate of HBV DNA > 107 copies/mL was higher in genotype C group than in genotype B group (36% vs. 28,6%, p > 0.05). Conclusions: Most of the patients had genotypes B or C. Patients with genotype C had positive HBeAg and may be related to higher serological HBV DNA level than in genotype B.

Sign in / Sign up

Export Citation Format

Share Document